Using data science and digital tech to accelerate medical innovation
Digital technologies are unlocking new ways of working and driving decision-making across the world. Whilst this is happening in almost every industry, the healthcare space – and Novartis in particular – is primed for disruption…
Feb 12, 2019
Medical innovation has never been a quick process. Developing a new medicine can take on average 12 years from lab bench to pharmacy shelf. It also requires significant investment; in the UK alone, Novartis spends around £30million on R&D each year. At Novartis, we’re hoping that new data and digital technologies can improve the efficiency of this process and bring important new medicines to patients faster, and also re-imagine the way these patients are diagnosed, treated, and supported in managing their health.
Fostering game-changing health innovation
This week we launched a new partnership with Wayra, a Telefónica-backed organisation that scales promising start-ups through investment and mentorship from industry experts across a range of industries. Our collaboration, The Health Hub, will specifically support start-ups to address some of healthcare’s biggest challenges in managing chronic conditions using ground-breaking, tech-focused solutions. The partnership will scale up these start-ups through investment, expertise and mentorship, and by cultivating an ecosystem of innovation where the start-ups can thrive together through networking and collaboration. Through this partnership, we hope to nurture a new generation of digital innovation in the NHS that will make a real difference to the health of the nation and support our NHS to be the best it can possibly be.
This isn’t the first time Novartis UK has supported innovation of this type. In June we teamed up with the British Cardiovascular Society and the Innovation Team of NHS England to run a hackathon, which was attended by health-tech experts, clinicians and programmers. By collaborating closely over two days, the group ‘hacked’ innovative solutions to improve patient outcomes in cardiology and reduce financial pressures on the NHS. These ideas are now being made a reality.
Harnessing data science to reveal new insights into disease
Data science and digital is setting the tone for Novartis in 2019. In January we announced a five-year partnership with the University of Oxford’s Big Data Institute. This collaboration will see us use powerful technologies like artificial intelligence to examine anonymised data from clinical trials, with the aim of spotting patterns that are undetectable to humans. Listen here as Chris Holmes, Principal Investigator at the Big Data Institute, explains how this works to the listeners of BBC Radio Oxford (listen from 1:42): https://www.bbc.co.uk/sounds/play/p06w12fj
The use of digital technologies is widening the scope of possibility in medical research, making it more efficient and more intelligent. We are supporting new technologies to flourish in the NHS and improve the health of the UK. It’s our ambition to use data and digital to reimagine medicine, and we share the Government’s drive to make the UK the best places in the world for the development and implementation of new health technologies.